---
created: 2025-04-13
updated: 2025-04-13T10:52
id: m`TJ6SZl$Y
specialty: immuno
specialty_id: 116
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::pembrolizumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions::pembrolizumab
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::cancer-immunotherapy
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::12000-12999::12048
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::14000-14999::14956
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::16000-16999::16895
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::1-highyield"
type: flashcard
---

# Question
Tumor cells upregulate **PD-L1** to evade anti-tumor T-cells

---

# Answer
PD-L1 will bind to PD1 on anti-tumor T cells and turn them off